DK2744826T3 - Kombinationsterapi med et anti-cd19-antistof og en purin-analog - Google Patents
Kombinationsterapi med et anti-cd19-antistof og en purin-analog Download PDFInfo
- Publication number
- DK2744826T3 DK2744826T3 DK12745883.4T DK12745883T DK2744826T3 DK 2744826 T3 DK2744826 T3 DK 2744826T3 DK 12745883 T DK12745883 T DK 12745883T DK 2744826 T3 DK2744826 T3 DK 2744826T3
- Authority
- DK
- Denmark
- Prior art keywords
- purin
- antibody
- analog
- combination therapy
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161523862P | 2011-08-16 | 2011-08-16 | |
| EP11177660 | 2011-08-16 | ||
| PCT/EP2012/065904 WO2013024095A1 (en) | 2011-08-16 | 2012-08-14 | Combination therapy with an anti - cd19 antibody and a purine analog |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2744826T3 true DK2744826T3 (da) | 2022-03-28 |
Family
ID=47714800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12745883.4T DK2744826T3 (da) | 2011-08-16 | 2012-08-14 | Kombinationsterapi med et anti-cd19-antistof og en purin-analog |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20140227277A1 (da) |
| EP (2) | EP2744826B1 (da) |
| JP (1) | JP6114273B2 (da) |
| KR (3) | KR102117202B1 (da) |
| CN (1) | CN103703027B (da) |
| AU (1) | AU2012296905B2 (da) |
| BR (1) | BR112013033916B1 (da) |
| CA (1) | CA2841738C (da) |
| DK (1) | DK2744826T3 (da) |
| ES (1) | ES2909720T3 (da) |
| HR (1) | HRP20220224T1 (da) |
| HU (1) | HUE058855T2 (da) |
| IL (1) | IL230295B (da) |
| LT (1) | LT2744826T (da) |
| MX (1) | MX353589B (da) |
| PL (1) | PL2744826T3 (da) |
| PT (1) | PT2744826T (da) |
| RS (1) | RS63121B1 (da) |
| RU (1) | RU2664462C9 (da) |
| SG (1) | SG10201606788VA (da) |
| SI (1) | SI2744826T1 (da) |
| WO (1) | WO2013024095A1 (da) |
| ZA (1) | ZA201401835B (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2514591A (en) * | 2013-05-30 | 2014-12-03 | Mologen Ag | Predictive biomarker for cancer therapy |
| ES2523901B1 (es) * | 2013-05-31 | 2015-12-02 | Universidad Autónoma de Madrid | Uso de la deguelina como terapia suplementaria de la leucemia linfoide crónica |
| IL249533A0 (en) * | 2014-06-16 | 2017-02-28 | Xencor Inc | Treatment of chronic lymphocytic leukemia |
| AU2015277516A1 (en) * | 2014-06-16 | 2016-12-22 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (CLL) |
| EP3603672A1 (en) | 2015-05-26 | 2020-02-05 | MorphoSys AG | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof |
| LT3337506T (lt) | 2015-08-21 | 2021-10-11 | Morphosys Ag | Deriniai ir jų panaudojimas |
| EA201892542A1 (ru) * | 2016-05-30 | 2019-06-28 | МорфоСис АГ | Способы прогнозирования у пациентов терапевтического эффекта терапии с использованием антител к cd19 |
| RU2756405C2 (ru) * | 2016-10-28 | 2021-09-30 | МорфоСис АГ | Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения |
| MA48751B1 (fr) | 2017-05-31 | 2023-11-30 | Morphosys Ag | Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax |
| US11634488B2 (en) | 2017-07-10 | 2023-04-25 | International—Drug—Development—Biotech | Treatment of B cell malignancies using afucosylated pro-apoptotic anti-CD19 antibodies in combination with anti CD20 antibodies or chemotherapeutics |
| WO2020150513A1 (en) * | 2019-01-17 | 2020-07-23 | Fred Hutchinson Cancer Research Center | Methods to enhance the selectivity and effectiveness of cancer treatments |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11852A (en) | 1854-10-31 | Abraham bassford | ||
| US106A (en) | 1915-08-24 | Specipication | ||
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| DE69939939D1 (de) * | 1998-08-11 | 2009-01-02 | Idec Pharma Corp | Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20-antikörpern |
| DE60042785D1 (de) | 1999-06-09 | 2009-10-01 | Immunomedics Inc | Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern |
| JP2004508420A (ja) | 2000-09-18 | 2004-03-18 | アイデック ファーマスーティカルズ コーポレイション | Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法 |
| ES2307832T3 (es) | 2001-12-03 | 2008-12-01 | Amgen Fremont Inc. | Clasificacion de anticuerpos basada en las caracteristicas de union. |
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| CA2534639C (en) | 2003-07-31 | 2013-07-30 | Immunomedics, Inc. | Anti-cd19 antibodies |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| US8444973B2 (en) | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
| AU2006262232A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | CD19 antibodies and their uses |
| US20070136826A1 (en) * | 2005-12-02 | 2007-06-14 | Biogen Idec Inc. | Anti-mouse CD20 antibodies and uses thereof |
| PT2270050E (pt) * | 2005-12-30 | 2013-09-12 | Merck Patent Gmbh | Anticorpos anti-cd19 com imunogenicidade reduzida |
| JP5825756B2 (ja) | 2006-08-14 | 2015-12-02 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ１９を標的とする最適化抗体 |
| PL2066349T3 (pl) | 2006-09-08 | 2012-09-28 | Medimmune Llc | Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych |
| CA2693053C (en) | 2007-05-30 | 2021-01-05 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| RU2476441C2 (ru) | 2007-10-19 | 2013-02-27 | Сиэтл Дженетикс, Инк. | Cd19-связывающие средства и их применение |
| US8679492B2 (en) | 2009-02-23 | 2014-03-25 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to CD19 and their uses |
| US20120128586A1 (en) | 2009-06-24 | 2012-05-24 | The Feinstein Institute For Medical Research | Method for treating chronic lymphocytic leukemia |
| TWI409079B (zh) * | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| BR112012003066A2 (pt) * | 2009-08-14 | 2016-11-16 | Roche Glycart Ag | uso de um anticorpo anti-cd20 defucosilado e composição compreendendo um anticorpo anti-cd20 defucosilado |
| AU2010314905A1 (en) * | 2009-11-06 | 2012-05-24 | Infinity Pharmaceuticals, Inc. | Oral formulations of a hedgehog pathway inhibitor |
-
2012
- 2012-08-14 LT LTEPPCT/EP2012/065904T patent/LT2744826T/lt unknown
- 2012-08-14 KR KR1020197022418A patent/KR102117202B1/ko active IP Right Grant
- 2012-08-14 ES ES12745883T patent/ES2909720T3/es active Active
- 2012-08-14 JP JP2014525432A patent/JP6114273B2/ja active Active
- 2012-08-14 DK DK12745883.4T patent/DK2744826T3/da active
- 2012-08-14 SG SG10201606788VA patent/SG10201606788VA/en unknown
- 2012-08-14 EP EP12745883.4A patent/EP2744826B1/en active Active
- 2012-08-14 KR KR1020147006942A patent/KR20140071368A/ko not_active Application Discontinuation
- 2012-08-14 PT PT127458834T patent/PT2744826T/pt unknown
- 2012-08-14 BR BR112013033916-0A patent/BR112013033916B1/pt active IP Right Grant
- 2012-08-14 SI SI201231992T patent/SI2744826T1/sl unknown
- 2012-08-14 PL PL12745883T patent/PL2744826T3/pl unknown
- 2012-08-14 HR HRP20220224TT patent/HRP20220224T1/hr unknown
- 2012-08-14 MX MX2013014935A patent/MX353589B/es active IP Right Grant
- 2012-08-14 RU RU2014103490A patent/RU2664462C9/ru active
- 2012-08-14 RS RS20220314A patent/RS63121B1/sr unknown
- 2012-08-14 CA CA2841738A patent/CA2841738C/en active Active
- 2012-08-14 CN CN201280036572.4A patent/CN103703027B/zh active Active
- 2012-08-14 US US14/127,217 patent/US20140227277A1/en not_active Abandoned
- 2012-08-14 WO PCT/EP2012/065904 patent/WO2013024095A1/en active Application Filing
- 2012-08-14 EP EP22155604.6A patent/EP4083071A3/en active Pending
- 2012-08-14 HU HUE12745883A patent/HUE058855T2/hu unknown
- 2012-08-14 AU AU2012296905A patent/AU2012296905B2/en active Active
- 2012-08-14 KR KR1020207014644A patent/KR20200060779A/ko active Application Filing
-
2014
- 2014-01-02 IL IL230295A patent/IL230295B/en active IP Right Grant
- 2014-03-12 ZA ZA2014/01835A patent/ZA201401835B/en unknown
-
2020
- 2020-04-03 US US16/839,903 patent/US20200352975A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2744826T3 (da) | Kombinationsterapi med et anti-cd19-antistof og en purin-analog | |
| LTC2785375I2 (lt) | Anti-pd-l1 antikūnai ir jų panaudojimas | |
| DK2917790T3 (da) | Horologe med opbevaret og interchangeable face | |
| DK3045187T3 (da) | Injektor og fremgangsmåde til samling | |
| DK2794654T3 (da) | Anti-phf-tau-antistoffer og deres anvendelser | |
| DK2723869T3 (da) | Il-15 og il-15r alpha-sushi-domænebaseret immunocytokiner | |
| DK2850202T3 (da) | Fremgangsmåder og grupper | |
| DK3262932T3 (da) | Genmodificerede mus med major histokompatibilitetskompleks | |
| BR112014000238A2 (pt) | método e artigo | |
| DK2914633T3 (da) | Antistof/lægemiddel-konjugater og anvendelsesfremgangsmåder | |
| BR112014009050A2 (pt) | pirrolbenzodiazepinas e conjugados destas | |
| DK2783216T3 (da) | Immunoassays med signalamplifikation | |
| DK2914291T3 (da) | Anti-komplement-c1s-antistoffer og anvendelser deraf | |
| DK3415157T3 (da) | N-acyldipeptidderivater og anvendelser deraf | |
| BR112014012137A2 (pt) | anticorpos anti-fgfr2 e suas utilizações | |
| EP2709543A4 (en) | INSTRUMENTS AND METHODS FOR EXPANSION | |
| CO6870003A2 (es) | Vacunas bovinas y métodos | |
| DK2668210T3 (da) | Anti-kit antistoffer og anvendelser deraf | |
| DK2744515T3 (da) | Kombinationsterapi med et anti-cd19-antistof og en nitrogensennep | |
| FI20116089L (fi) | Järjestely ja laite | |
| BR112013022766A2 (pt) | método de administração de d-pirfenidona e kit | |
| HK1200334A1 (en) | Combination therapy using immunoglobulin and c1-inhibitor c1- | |
| DK2556200T3 (da) | Gitterskinne med åben krop | |
| DK2704744T3 (da) | Komplementfaktor-b-analoger og anvendelser deraf | |
| EP2694042A4 (en) | CONJUGATES OF ACTIVATED NUCLEOSIDE ANALOGUE AND METHODS OF USING SAME |